As Rainbow Coral Corp. (OTCBB: RBCC) works to market and develop an
innovative new 3D bioprinting system, new 3D printing innovations are
generating massive new demand for the technology from patients and
doctors alike in the medical industry.
Just days ago, it was reported worldwide that a British surgeon
successfully used the latest 3D printing techniques to create a new
pelvis for a man who had lost half of his own to bone cancer. It was the
first, groundbreaking transplant of its kind, but hardly the only
medical breakthrough to arise through 3D printing.
The revolutionary technology is moving the entire healthcare sector
forward. 3D printers have been used to create prosthetic limbs, custom
hearing aids and even human tissues.
RBCC is well-positioned to capitalize on the rise of 3D printing in
medicine thanks to its joint venture with Nano3D Biosciences (n3D). The
companies have teamed up to market and develop the BiO Assay, the first
commercially available 3D bioprinter designed specifically for rapid,
high-volume drug screening.
The automated toxicity assay uses biocompatible magnetic nanoparticles
to print cells into 3D structures more affordably than competing
bioprinting tech currently on the market. The BiO Assay represents a sea
change in harmaceutical research, offering better and faster results
than have previously been possible.
RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and
develop new medical and research technology innovations to compete
alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott
Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow
Biosciences acquired an equity interest in n3D.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
[ Back To NFVZone's Homepage ]